Found: 77
Select item for more details and to access through your institution.
Phase transitions of CFTs with holographic duals.
- Published in:
- Fortschritte der Physik / Progress of Physics, 2002, v. 50, n. 8/9, p. 942, doi. 10.1002/1521-3978(200209)50:8/9<942::AID-PROP942>3.0.CO;2-V
- By:
- Publication type:
- Article
Ideas on the semi-Classical Path Integral over Embedded Manifolds.
- Published in:
- Fortschritte der Physik / Progress of Physics, 2001, v. 49, n. 4-6, p. 607, doi. 10.1002/1521-3978(200105)49:4/6<607::AID-PROP607>3.0.CO;2-I
- By:
- Publication type:
- Article
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667).
- Published in:
- 2011
- By:
- Publication type:
- Abstract
No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of ricochet (BAY 63-2521) and aspirin.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
BAY 58-2667, a soluble guanylate cyclase activator, has a favourable safety profile and reduces peripheral vascular resistance in healthy male volunteers.
- Published in:
- 2007
- By:
- Publication type:
- Abstract
BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers.
- Published in:
- 2007
- By:
- Publication type:
- Abstract
The effect of food on the absorption and pharmacokinetics of rivaroxaban.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2013, v. 51, n. 7, p. 549, doi. 10.5414/CP201812
- By:
- Publication type:
- Article
Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms.
- Published in:
- Biopharmaceutics & Drug Disposition, 2015, v. 36, n. 2, p. 93, doi. 10.1002/bdd.1923
- By:
- Publication type:
- Article
Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation.
- Published in:
- PLoS ONE, 2011, v. 6, n. 4, p. 1, doi. 10.1371/journal.pone.0017626
- By:
- Publication type:
- Article
Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1999, v. 65, n. 3, p. 251, doi. 10.1016/S0009-9236(99)70104-9
- By:
- Publication type:
- Article
Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study.
- Published in:
- Thrombosis Journal, 2018, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12959-018-0185-1
- By:
- Publication type:
- Article
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.
- Published in:
- Thrombosis Journal, 2013, v. 11, n. 1, p. 10, doi. 10.1186/1477-9560-11-10
- By:
- Publication type:
- Article
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2014, v. 78, n. 2, p. 353, doi. 10.1111/bcp.12349
- By:
- Publication type:
- Article
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 76, n. 1, p. 89, doi. 10.1111/bcp.12054
- By:
- Publication type:
- Article
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 76, n. 3, p. 455, doi. 10.1111/bcp.12075
- By:
- Publication type:
- Article
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
- Published in:
- British Journal of Clinical Pharmacology, 2012, v. 74, n. 1, p. 86, doi. 10.1111/j.1365-2125.2012.04181.x
- By:
- Publication type:
- Article
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 70, n. 5, p. 703, doi. 10.1111/j.1365-2125.2010.03753.x
- By:
- Publication type:
- Article
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.
- Published in:
- British Journal of Clinical Pharmacology, 2009, v. 68, n. 1, p. 77, doi. 10.1111/j.1365-2125.2009.03390.x
- By:
- Publication type:
- Article
On the number of soft quanta in classical field configurations.
- Published in:
- Canadian Journal of Physics, 2014, v. 92, n. 9, p. 973, doi. 10.1139/cjp-2013-0712
- By:
- Publication type:
- Article
Spectral functions in holographic renormalization group flows.
- Published in:
- Journal of High Energy Physics, 2009, v. 2009, n. 1, p. 060, doi. 10.1088/1126-6708/2009/01/060
- By:
- Publication type:
- Article
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Effects of omeprazole and AlOH/MgOH on riociguat absorption.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat.
- Published in:
- 2013
- By:
- Publication type:
- Abstract
Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor.
- Published in:
- Frontiers in Physiology, 2014, v. 5, p. 1, doi. 10.3389/fphys.2014.00417
- By:
- Publication type:
- Article
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
- Published in:
- European Journal of Clinical Pharmacology, 2021, v. 77, n. 4, p. 527, doi. 10.1007/s00228-020-03023-7
- By:
- Publication type:
- Article
Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics.
- Published in:
- AAPS Open, 2022, v. 8, n. 1, p. 1, doi. 10.1186/s41120-022-00063-4
- By:
- Publication type:
- Article
Beyond AdS<sub>2</sub>/dCFT<sub>1</sub>: insertions in two Wilson loops.
- Published in:
- Journal of High Energy Physics, 2023, v. 2023, n. 10, p. 1, doi. 10.1007/JHEP10(2023)127
- By:
- Publication type:
- Article
Semiclassical quantization of the superstring and Hagedorn temperature.
- Published in:
- Journal of High Energy Physics, 2023, v. 2023, n. 8, p. 1, doi. 10.1007/JHEP08(2023)185
- By:
- Publication type:
- Article
Reparameterization dependence is useful for holographic complexity.
- Published in:
- Journal of High Energy Physics, 2021, v. 2021, n. 7, p. 1, doi. 10.1007/JHEP07(2021)010
- By:
- Publication type:
- Article
Exact 1/N expansion of Wilson loop correlators in N = 4 Super-Yang-Mills theory.
- Published in:
- Journal of High Energy Physics, 2021, v. 2021, n. 7, p. 1, doi. 10.1007/JHEP07(2021)001
- By:
- Publication type:
- Article
Combinatorics of Wilson loops in N 4 SYM theory.
- Published in:
- Journal of High Energy Physics, 2019, v. 2019, n. 11, p. 1, doi. 10.1007/JHEP11(2019)096
- By:
- Publication type:
- Article
Note on generating functions and connected correlators of 1/2-BPS Wilson loops in N = 4 SYM theory.
- Published in:
- Journal of High Energy Physics, 2019, v. 2019, n. 8, p. N.PAG, doi. 10.1007/JHEP08(2019)149
- By:
- Publication type:
- Article
Generalized supergravity equations and generalized Fradkin-Tseytlin counterterm.
- Published in:
- Journal of High Energy Physics, 2019, v. 2019, n. 5, p. 1, doi. 10.1007/JHEP05(2019)063
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 10, p. 1195, doi. 10.1002/psp4.12688
- By:
- Publication type:
- Article
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 11, p. 805, doi. 10.1002/psp4.12444
- By:
- Publication type:
- Article
Integrated Population Pharmacokinetic Analysis of Rivaroxaban Across Multiple Patient Populations.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2018, v. 7, n. 5, p. 309, doi. 10.1002/psp4.12288
- By:
- Publication type:
- Article
Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen.
- Published in:
- British Journal of Clinical Pharmacology, 2007, v. 63, n. 4, p. 469, doi. 10.1111/j.1365-2125.2006.02776.x
- By:
- Publication type:
- Article
Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban.
- Published in:
- Clinical Pharmacokinetics, 2014, v. 53, n. 1, p. 89, doi. 10.1007/s40262-013-0090-5
- By:
- Publication type:
- Article
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban.
- Published in:
- Clinical Pharmacokinetics, 2014, v. 53, n. 1, p. 1, doi. 10.1007/s40262-013-0100-7
- By:
- Publication type:
- Article
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Rivaroxaban.
- Published in:
- Clinical Pharmacokinetics, 2011, v. 50, n. 10, p. 675, doi. 10.2165/11595320-000000000-00000
- By:
- Publication type:
- Article
Population Pharmacokinetics and Pharmacodynamics of Cinaciguat, a Soluble Guanylate Cyclase Activator, in Patients with Acute Decompensated Heart Failure.
- Published in:
- Clinical Pharmacokinetics, 2010, v. 49, n. 2, p. 119, doi. 10.2165/11317590-000000000-00000
- By:
- Publication type:
- Article
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
- Published in:
- 2008
- By:
- Publication type:
- journal article
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery
- Published in:
- Clinical Pharmacokinetics, 2008, v. 47, n. 3, p. 203, doi. 10.2165/00003088-200847030-00006
- By:
- Publication type:
- Article
The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 3, p. 249, doi. 10.1002/jcph.5
- By:
- Publication type:
- Article